, Cancer Cell Biology J_ID: z3q Customer A_ID: IJC28594 Cadmus Art: IJC28594 Ed. Ref. No.: 13-1229.R2 Date: 25-November-13 Stage, p.11
, ID: jwweb3b2server Time: 16:02 I Path
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected nonsmall-cell lung cancer, Ann Oncol, vol.15, pp.28-32, 2004. ,
Epidermal growth factor receptor inhibition in lung cancer: status 2012, J Thorac Oncol, vol.8, pp.373-84, 2013. ,
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors, Sci Transl Med, vol.3, pp.75-101, 2011. ,
The multiple roles of amphiregulin in human cancer, Biochim Biophys Acta Rev Cancer, vol.1816, pp.119-150, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00602082
Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax-and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells, J Biol Chem, vol.280, pp.19757-67, 2005. ,
URL : https://hal.archives-ouvertes.fr/inserm-00340599
Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines, J Biol Chem, vol.277, pp.49127-49160, 2002. ,
Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers, Mol Ther, vol.18, pp.528-563, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00425468
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma, J Pathol, vol.225, pp.83-95, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00598462
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype, J Thorac Oncol, vol.4, pp.1126-1161, 2009. ,
Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation, Mol Ther, vol.18, pp.536-579, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00425467
Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas, Hum Pathol, vol.42, pp.214-240, 2011. ,
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, vol.316, pp.1039-1082, 2007. ,
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt, Cancer Res, vol.67, pp.5779-88, 2007. ,
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines, Adv Med Sci, vol.56, pp.275-84, 2011. ,
Histone deacetylases and cancer, Mol Oncol, 2012. ,
Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients, Int J Cancer, vol.112, pp.26-32, 2004. ,
Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis, Mol Cell, vol.13, pp.627-665, 2004. ,
HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma, Neoplasia, vol.13, pp.726-760, 2011. ,
Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells, Mol Cancer Ther, vol.5, pp.2767-76, 2006. ,
The human Sir2 ortholog, SIRT2, is an NAD1-dependent tubulin deacetylase, Mol Cell, vol.11, pp.437-481, 2003. ,
p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells, Proc Natl Acad Sci, vol.95, pp.6791-6797, 1998. ,
Perturbations of the AKT signaling pathway in human cancer, Oncogene, vol.24, pp.7455-64, 2005. ,
Activation of AKT kinases in cancer: implications for therapeutic targeting, Adv Cancer Res, vol.94, pp.29-86, 2005. ,
Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation, Cancer Res, vol.61, pp.3986-97, 2001. ,
Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer, Clin Cancer Res, vol.11, pp.2930-2936, 2005. ,
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer, J Natl Cancer Inst, vol.96, pp.1133-1174, 2004. ,
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, vol.2, p.17, 2005. ,
Mutations and response to epidermal growth factor receptor inhibitors, Clin Cancer Res, vol.15, pp.1133-1142, 2009. ,
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?, J Clin Oncol, vol.28, pp.4769-77, 2010. ,
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome, J Natl Cancer Inst, vol.104, pp.228-267, 2012. ,
Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization, Cell Death Differ, vol.16, pp.758-69, 2009. ,
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins, J Cell Biochem, vol.113, pp.2167-77, 2012. ,
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor, Proc Natl Acad Sci, vol.101, pp.15064-15073, 2004. ,
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung, Lung Cancer, vol.74, pp.300-304, 2011. ,
Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer, Biochim Biophys Acta, vol.1815, pp.241-52, 2011. ,
Mammalian sirtuins: biological insights and disease relevance, Annu Rev Pathol, vol.5, pp.253-95, 2010. ,
SIRT1 promotes DNA repair activity and deacetylation of Ku70, Exp Mol Med, vol.39, pp.8-13, 2007. ,
SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70, Mol Cell Biol, vol.28, pp.6384-401, 2008. ,
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase, Science, vol.305, pp.390-392, 2004. ,
Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients, Neoplasia, vol.11, pp.763-70, 2009. ,
Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation, Proc Natl Acad Sci, vol.105, pp.5117-5139, 2008. ,
at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination, Oncogene, vol.26, pp.5468-76, 2007. ,
Histone deacetylase 10 promotes autophagy-mediated cell survival, Proc Natl Acad Sci, vol.110, pp.2592-601, 2013. ,
Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A, J Am Chem Soc, vol.132, pp.10842-10848, 2010. ,
HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin, Oncol Rep, vol.27, pp.819-843, 2012. ,
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells, PLoS One, vol.6, p.22739, 2011. ,
The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy, Sci Signal, vol.4, p.46, 2011. ,
Targeting the phosphoinositide 3-kinase pathway in cancer, Nat Rev Drug Discov, vol.8, pp.627-671, 2009. ,
The PI3K pathway as drug target in human cancer, J Clin Oncol, vol.28, pp.1075-83, 2010. ,
Pharmacodynamic markers of perifosine efficacy, Clin Cancer Res, vol.13, pp.7421-7452, 2007. ,
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT, Invest New Drugs, vol.29, pp.1381-1390, 2011. ,
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors, J Clin Oncol, vol.30, pp.282-90, 2012. ,
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity, Cancer Cell, vol.19, pp.58-71, 2011. ,